Development of the rat model of lapatinib-induced diarrhoea

Simple item page
dc.contributor.authorBowen, J.
dc.date.issued2014
dc.description.abstractTargeted therapy of cancer is often associated with clinically significant diarrhoea; however, the mechanisms underpinning this adverse effect are currently unknown. Diarrhoea following treatment with tyrosine kinase inhibitors (TKIs) of EGFR is particularly troublesome. Until recently, understanding of EGFR TKI-induced diarrhoea has been limited to clinical observation. However, our group has recently developed the first rat model of EGFR TKI-induced diarrhoea. This paper reviews the published and unpublished findings.
dc.description.statementofresponsibilityJoanne M. Bowen
dc.identifier.citationScientifica, 2014; 2014:194185-1-194185-6
dc.identifier.doi10.1155/2014/194185
dc.identifier.issn2090-908X
dc.identifier.issn2090-908X
dc.identifier.orcidBowen, J. [0000-0003-0876-0031]
dc.identifier.urihttp://hdl.handle.net/2440/95947
dc.language.isoen
dc.publisherHindawi Publishing Corporation
dc.rights© 2014 Joanne M. Bowen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.source.urihttps://doi.org/10.1155/2014/194185
dc.titleDevelopment of the rat model of lapatinib-induced diarrhoea
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_95947.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications